Pharmacokinetics of Intravenous Conivaptan in Subjects With Hepatic or Renal Impairment

被引：0
|
作者：
Michael J. Roy
Keith A. Erdman
Anura T. Abeyratne
Lisa C. Plumb
Kenneth Lasseter
Dennis S. Riff
James J. Keirns
机构：
[1] Astellas Pharma Global Development,
[2] Inc.,undefined
[3] Clinical Pharmacology of Miami,undefined
[4] Inc.,undefined
[5] Advanced Clinical Research Institute,undefined
来源：
Clinical Pharmacokinetics | 2013年 / 52卷
关键词：
Hepatic Impairment; Tolvaptan; Moderate Renal Impairment; Moderate Hepatic Impairment; Conivaptan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：385 / 395
页数：10
相关论文
共 50 条
  • [1] Pharmacokinetics of Intravenous Conivaptan in Subjects With Hepatic or Renal Impairment
    Roy, Michael J.
    Erdman, Keith A.
    Abeyratne, Anura T.
    Plumb, Lisa C.
    Lasseter, Kenneth
    Riff, Dennis S.
    Keirns, James J.
    CLINICAL PHARMACOKINETICS, 2013, 52 (05) : 385 - 395
  • [2] Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment
    Angelika Weil
    Paul Martin
    Robert Smith
    Stuart Oliver
    Peter Langmuir
    Jessica Read
    Karl-Heinz Molz
    Clinical Pharmacokinetics, 2010, 49 : 607 - 618
  • [3] Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment
    Flanagan, S.
    Minassian, S. L.
    Morris, D.
    Ponnuraj, R.
    Marbury, T. C.
    Alcorn, H. W.
    Fang, E.
    Prokocimer, P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) : 6471 - 6476
  • [4] Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment
    Weil, Angelika
    Martin, Paul
    Smith, Robert
    Oliver, Stuart
    Langmuir, Peter
    Read, Jessica
    Molz, Karl-Heinz
    CLINICAL PHARMACOKINETICS, 2010, 49 (09) : 607 - 618
  • [5] A Phase 1, Open-Label Study of Intravenous Conivaptan in Subjects with Hepatic Impairment
    Roy, Michael
    Erdman, Keith
    Abeyratne, Anura
    Plumb, Lisa
    Lasseter, Kenneth
    Keirns, Jim
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1361 - 1361
  • [6] Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
    Marbury, Thomas
    Fox, Jerry
    Kaelin, Byron
    Pavliv, Leo
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 373 - 382
  • [7] Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment
    Xin, Yan
    Kawashima, Jun
    Weng, Winnie
    Kwan, Ellen
    Tarnowski, Thomas
    Silverman, Jeffrey A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (04): : 522 - 532
  • [8] Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment
    Jacobsen, LV
    Popescu, G
    Plum, A
    DIABETES, 2002, 51 : A102 - A102
  • [9] Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment
    Puttonen, Jaakko
    Kantele, Sampo
    Ruck, Angela
    Ramela, Meri
    Hakkinen, Sari
    Kivikko, Matti
    Pentikainen, Pertti J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (04): : 445 - 454
  • [10] Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment.
    Jacobsen, LV
    Popescu, G
    Plum, A
    DIABETOLOGIA, 2002, 45 : A259 - A260
12345